journal article·2025-02Open access

A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” Immunity

Jiayan Fu, Shuangqi Wu, Nengcheng Bao, Lili Wu, Huiru Qu, Zhechao Wang, Haiyang Dong, Jian Wu, Yongfeng Jin

Advanced Science· Volume 12· Issue 8

Abstract

Abstract Personalized neoantigen cancer mRNA vaccines are promising candidates for precision medicine. However, the difficulty of identifying neoantigens heavily hinders their broad applicability. This study developed a universal strategy of anti‐tumor mRNA vaccine by harnessing “off‐the‐shelf” immunity to known antigens. First, the model antigen ovalbumin (OVA) is used for mRNA vaccine design. In vitro test indicated that this mRNA vaccine reprogrammed tumor cells that can be recognized and killed by OVA‐specific cytotoxic T lymphocytes (CTLs). In situ mRNA vaccine notably inhibited tumor growth across three subcutaneous solid tumor models in mice. Further single‐cell sequencing analyses revealed that mRNA vaccination act to reshape the immunosuppressive tumor microenvironment (TME) toward more proinflammatory characteristics. Strikingly, this framework of mRNA‐based strategy can be applied to two clinical pathogen antigens, hepatitis B surface antigen (HBsAg), and SARS‐CoV‐2 spike receptor‐binding domain (SRBD). Interestingly, the mRNA‐based strategy largely recapitulated the scenario of spontaneous cancer regression following pathogen infection or vaccination. Collectively, this study provides not only proof of concept for universal anti‐tumor mRNA therapy, but also mechanistic insights in echoing the long‐standing puzzle of spontaneous cancer regression.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · CAR-T cell therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Key Laboratory of Advanced Drug Delivery and Release Systems Zhejiang University Hangzhou Zhejiang 310058 China

MOE Laboratory of Biosystems Homeostasis & Protection Innovation Center for Cell Signaling Network College of Life Sciences Zhejiang University Hangzhou Zhejiang 310058 China

Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang 310006 China

Funding

National Key Research and Development Program of China · Fundamental Research Funds for the Central Universities

References (62)

Show source-provided references
1. 10.1186/s12943-019-1055-610.1186/s12943-019-1055-6 ↗
2. 10.1126/science.aaa497110.1126/science.aaa4971 ↗
3. 10.1186/s12943-021-01452-110.1186/s12943-021-01452-1 ↗
4. 10.1007/s00018-018-2935-410.1007/s00018-018-2935-4 ↗
5. 10.1093/cid/ciab88410.1093/cid/ciab884 ↗
6. 10.7150/ijbs.8373210.7150/ijbs.83732 ↗
7. 10.3389/fimmu.2021.67235610.3389/fimmu.2021.672356 ↗
8. 10.1038/s41571-020-00460-210.1038/s41571-020-00460-2 ↗
9. 10.1186/s40364-023-00449-w10.1186/s40364-023-00449-w ↗
10. 10.1038/s41568-023-00586-210.1038/s41568-023-00586-2 ↗
11. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
12. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
13. 10.1038/srep0892410.1038/srep08924 ↗
14. 10.3389/fimmu.2018.0094710.3389/fimmu.2018.00947 ↗
15. 10.1056/NEJMoa101286310.1056/NEJMoa1012863 ↗
16. 10.1126/scitranslmed.aaw156510.1126/scitranslmed.aaw1565 ↗
17. 10.1016/j.clml.2012.06.00710.1016/j.clml.2012.06.007 ↗
18. 10.1111/1440-1681.1309610.1111/1440-1681.13096 ↗
19. 10.1186/s12967-023-04110-w10.1186/s12967-023-04110-w ↗
20. 10.1111/bjh.1711610.1111/bjh.17116 ↗
21. 10.1007/s00259-021-05275-610.1007/s00259-021-05275-6 ↗
22. 10.3390/ijms2409780310.3390/ijms24097803 ↗
23. 10.3390/ijms2403232610.3390/ijms24032326 ↗
24. 10.1007/s12192-021-01211-710.1007/s12192-021-01211-7 ↗
25. Sousa L. G. · Journal for immunotherapy of cancer · 2022 · 1010.1136/jitc-2021-004371 ↗
26. 10.1111/bjd.2063010.1111/bjd.20630 ↗
27. 10.1038/ni.256810.1038/ni.2568 ↗
28. 10.1038/mt.2012.23310.1038/mt.2012.233 ↗
29. 10.1038/s41587-019-0404-810.1038/s41587-019-0404-8 ↗
30. 10.3389/fimmu.2019.0196210.3389/fimmu.2019.01962 ↗
31. 10.1186/s12943-022-01574-010.1186/s12943-022-01574-0 ↗
32. 10.1080/2162402X.2023.220786810.1080/2162402X.2023.2207868 ↗
33. 10.1038/s41467-019-08534-110.1038/s41467-019-08534-1 ↗
34. 10.1093/protein/gzs03310.1093/protein/gzs033 ↗
35. 10.1016/j.cell.2022.01.01510.1016/j.cell.2022.01.015 ↗
36. 10.1126/science.110036910.1126/science.1100369 ↗
37. 10.1038/s41416-020-01048-410.1038/s41416-020-01048-4 ↗
38. 10.1038/s41568-023-00560-y10.1038/s41568-023-00560-y ↗
39. 10.1016/j.immuni.2019.03.00910.1016/j.immuni.2019.03.009 ↗
40. 10.1038/s41586-022-05400-x10.1038/s41586-022-05400-x ↗
41. 10.1016/S0140-6736(14)60220-810.1016/S0140-6736(14)60220-8 ↗
42. 10.1016/j.nbt.2009.01.00110.1016/j.nbt.2009.01.001 ↗
43. 10.1056/NEJMra100168310.1056/NEJMra1001683 ↗
44. 10.1038/s41422-020-00392-710.1038/s41422-020-00392-7 ↗
45. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
46. 10.1002/hep.2740610.1002/hep.27406 ↗
47. 10.1038/s41541-022-00478-w10.1038/s41541-022-00478-w ↗
48. 10.1126/science.105886710.1126/science.1058867 ↗
49. 10.1016/S1470-2045(20)30234-510.1016/S1470-2045(20)30234-5 ↗
50. 10.1038/s41568-022-00442-910.1038/s41568-022-00442-9 ↗
51. 10.1186/1471-2407-11-45410.1186/1471-2407-11-454 ↗
52. 10.4161/onci.2092610.4161/onci.20926 ↗
53. 10.1136/jitc-2023-00719810.1136/jitc-2023-007198 ↗
54. Pasin F. · Acta bio‐medica : Atenei Parmensis · 2020 · 91
55. 10.1038/s41586-018-0130-210.1038/s41586-018-0130-2 ↗
56. 10.1111/febs.1549910.1111/febs.15499 ↗
57. 10.1038/s41563-023-01472-w10.1038/s41563-023-01472-w ↗
58. 10.1158/1078-0432.CCR-20-047210.1158/1078-0432.CCR-20-0472 ↗
59. 10.1089/nat.2018.073410.1089/nat.2018.0734 ↗
60. 10.3402/jev.v5.3105310.3402/jev.v5.31053 ↗
61. 10.3389/fcell.2021.78942710.3389/fcell.2021.789427 ↗
62. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗